Medicus Pharma (MDCX) vs Skye Bioscience (SKYE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Skye Bioscience is the larger company by market cap ($7.4 million vs $7.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MDCX | SKYE |
|---|---|---|
| Share price | $0.1019 | $1.68 |
| Market cap | $7.31M | $7.44M |
| 1-day change | -36.39% | +1.82% |
| YTD return | -93.34% | — |
| 1-year return | -95.86% | — |
| EPS (TTM) | $-2.38 | $-10.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.78 | $14.08 |
| 52-week low | $0.0941 | $1.50 |
| Distance from 52-week high | -96.33% | -88.07% |
| Analyst consensus | none | none |
| Avg. price target upside | +4316.09% | +3947.62% |
| Average volume | 4.43M | 89.28K |
| Shares outstanding | 71.71M | 4.43M |
| Employees | 16 | 2 |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Medicus Pharma
MDCX stock →Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin.
Healthcare · Drug Manufacturers - General · 16 employees
About Skye Bioscience
SKYE stock →Skye Bioscience, Inc., a clinical-stage biotechnology company, develops molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related metabolic diseases. The company's lead clinical asset is nimacimab, a peripherally-restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1) administered as a subcutaneous injectable, which targets CB1 receptors in peripheral tissues including adipose, liver, and muscle tissues with limited central nervous system accumulation.
Healthcare · Biotechnology · 2 employees
MDCX vs SKYE FAQ
Which is bigger, Medicus Pharma or Skye Bioscience?
Skye Bioscience (SKYE) is larger, with a market capitalization of $7.44M compared with $7.31M for Medicus Pharma (MDCX).
Are Medicus Pharma and Skye Bioscience in the same industry?
Both are in the Healthcare sector, but in different industries: Drug Manufacturers - General for Medicus Pharma and Biotechnology for Skye Bioscience.